Lonza and ABL Bio collaborate on development and manufacture of new bispecific antibody product
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
Women of all ages will get round-the-clock access to comprehensive treatment
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Rocuronium Bromide Injection is a neuromuscular blocking agent
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Subscribe To Our Newsletter & Stay Updated